Literature DB >> 34665319

Clinical Characteristics of Sarcoidosis Patients with Self-Reported Lymphoma: A US Nationwide Registry Study.

Bashar N Alzghoul1, Yazan Zayed2, Ahmad Obeidat3, Bara Alzghoul4, Abdallah Naser5, Abdul-Rahim Shilbayeh6, Ayoub Innabi2, Tamara Al-Hakim7, Mindy Buchanan7, Borna Mehrad2, Divya C Patel2.   

Abstract

PURPOSE: Little is known about the association between sarcoidosis and lymphoma. We aim to determine the prevalence of lymphoma in US sarcoidosis patients and compare the clinical characteristics of patients with and without lymphoma.
METHODS: Using a national registry-based study investigating 3560 respondents to the Foundation for Sarcoidosis Research Sarcoidosis Advanced Registry for Cures Questionnaire (FSR-SARC) completed between June 2014 and August 2019, we identified patients who reported the diagnosis of lymphoma following sarcoidosis and randomly selected a computer-generated control sample of sarcoidosis patients with no reported lymphoma with a 2:1 ratio.
RESULTS: Among 3560 patients with sarcoidosis, 43 (1.2%) reported developing lymphoma following their sarcoidosis diagnosis. Patients with lymphoma were more likely to be diagnosed with sarcoidosis at a younger age (median, IQR) 40 (27-50) vs 45 (34.8-56, p = 0.017) years, were more likely to be African-Americans OR 95% CI 3.9 (1.6-9.6, p = 0.002), and have low annual income (OR 2.7, 1.1-6.4 p = 0.026). The sarcoidosis-lymphoma group were more likely to have salivary gland (16% vs 5%, p = 0.026) (OR 4; 1.1-14.5) and cutaneous (46% vs 23%, p = 0.023) (OR 2.9; 1.1-7.3) sarcoidosis. They also reported more chronic fatigue (42% vs 23%, p = 0.029), chronic pain (37% vs 13%, p = 0.001), and depression (42% vs 22%, p = 0.019).
CONCLUSION: The prevalence of lymphoma reported in sarcoidosis patients is higher than the general population which further supports the possible increased risk of lymphoma in sarcoidosis. Diagnosis of sarcoidosis at a younger age, African-American race, cutaneous, and salivary glands sarcoidosis were associated with lymphoma. Sarcoidosis patients who developed lymphoma reported higher disease burden and more non-organ-specific manifestations.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer; Lymphoma; Sarcoidosis

Mesh:

Year:  2021        PMID: 34665319      PMCID: PMC8627493          DOI: 10.1007/s00408-021-00485-z

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  29 in total

Review 1.  Sarcoidosis and lymphoma: case series and literature review.

Authors:  H Maayan; Y Ashkenazi; A Nagler; G Izbicki
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2011-10       Impact factor: 0.670

Review 2.  Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

3.  Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype.

Authors:  M Fallah; X Liu; J Ji; A Försti; K Sundquist; K Hemminki
Journal:  Ann Oncol       Date:  2014-04-08       Impact factor: 32.976

4.  Rituximab in the treatment of refractory pulmonary sarcoidosis.

Authors:  Nadera J Sweiss; Elyse E Lower; Mehdi Mirsaeidi; Steven Dudek; Joe G N Garcia; David Perkins; Patricia W Finn; Robert P Baughman
Journal:  Eur Respir J       Date:  2014-01-31       Impact factor: 16.671

5.  Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases.

Authors:  M Kornacker; A Kraemer; E Leo; A D Ho
Journal:  Ann Hematol       Date:  2002-01-10       Impact factor: 3.673

6.  Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study.

Authors:  M Fallah; X Liu; J Ji; A Försti; K Sundquist; K Hemminki
Journal:  Ann Oncol       Date:  2014-07-31       Impact factor: 32.976

7.  Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.

Authors:  Pier Luigi Zinzani; Monica Tani; Rocco Trisolini; Stefano Fanti; Vittorio Stefoni; Marco Alifano; Paolo Castellucci; Gerardo Musuraca; Giorgia Dalpiaz; Lapo Alinari; Enrica Marchi; Mariapaola Fina; Cinzia Pellegrini; Mohsen Farsad; Alessandra Cancellieri; Annalisa Busca; Romeo Canini; Stefano Pileri; Michele Baccarani; Maurizio Boaron
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

Review 8.  Sarcoidosis and cancer risk: systematic review and meta-analysis of observational studies.

Authors:  Martina Bonifazi; Francesca Bravi; Stefano Gasparini; Carlo La Vecchia; Armando Gabrielli; Athol U Wells; Elisabetta A Renzoni
Journal:  Chest       Date:  2015-03       Impact factor: 9.410

Review 9.  Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature.

Authors:  Jonathan London; Aurélie Grados; Christophe Fermé; Alexandre Charmillon; François Maurier; Bénédicte Deau; Etienne Crickx; Pauline Brice; Catherine Chapelon-Abric; Corinne Haioun; Barbara Burroni; Marco Alifano; Claire Le Jeunne; Loïc Guillevin; Nathalie Costedoat-Chalumeau; Nicolas Schleinitz; Luc Mouthon; Benjamin Terrier
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

10.  The incidence of malignant tumours in patients with respiratory sarcoidosis.

Authors:  H Brincker; E Wilbek
Journal:  Br J Cancer       Date:  1974-03       Impact factor: 7.640

View more
  1 in total

1.  LUNG Year in Review: 2021.

Authors:  Peter V Dicpinigaitis
Journal:  Lung       Date:  2022-01-18       Impact factor: 3.777

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.